

## WEST Search History

DATE: Monday, August 11, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L6	l1 and l2 and l5	29	L6
L5	mg or mg. or mg\$	923753	L5
L4	mg or mg.	834559	L4
L3	mg	834557	L3
L2	nocardia or actinosynnema	3467	L2
L1	maytansinoid\$ or ansamitocin\$	172	L1

END OF SEARCH HISTORY

QUE (MAYTANSINOID OR MAYTANSINIDS OR ANSAMITOCIN OR ANSAMITOCI  
-----

FILE 'CAPLUS, BIOTECHDS, USPATFULL, CANCERLIT, TOXCENTER, USPAT2' ENTERED  
AT 08:40:24 ON 11 AUG 2003

L2 11 S L1  
L3 9 DUP REM L2 (2 DUPLICATES REMOVED)

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.85	44.86

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.95	-1.95

CA SUBSCRIBER PRICE

APLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2  
 AN 2001:763222 CAPLUS  
 DN 135:302951  
 TI Methods for ansamitocin production  
 IN Fulston, Mark; Stefanska, Anna; Thirkettle, Jan  
 PA SmithKline Beecham P.L.C., UK  
 SO PCT Int. Appl., 13 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077360	A2	20011018	WO 2001-GB1661	20010411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002015984	A1	20020207	US 2001-828758	20010409
	US 6573074	B2	20030603		
	EP 1272653	A2	20030108	EP 2001-966770	20010411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2002004893	A	20021010	NO 2002-4893	20021010
PRAI	US 2000-196361P	P	20000412		
	WO 2001-GB1661	W	20010411		

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from *Actinosynnema pretiosum* containing 86.3 mg/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 mg/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation. At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation. This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of

**ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins**.

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from *Actinosynnema pretiosum* containing 86.3 mg/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 mg/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation. At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation. This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in

toluene mobile phase. The **ansamitocin** P-3 fractions were  
combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g  
of **ansamitocin** P-3. This solid was taken up in 200 mL Et acetate,  
warmed to 40 °C, combined with 200 mL heptane and allowed to cool.  
Once seeded with pure **ansamitocin** P-3 crystals the crystallization  
occurred spontaneously. A yield of 2.5 g of crystals was obtained containing  
86% (2.15 g) **ansamitocin** P-3 with the remainder consisting  
mostly of other **ansamitocins**.

APLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2

AN 2001:763222 CAPLUS

DN 135:302951

TI Methods for ansamitocin production

IN Fulston, Mark; Stefanska, Anna; Thirkettle, Jan

PA SmithKline Beecham P.L.C., UK

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077360	A2	20011018	WO 2001-GB1661	20010411
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002015984	A1	20020207	US 2001-828758	20010409
	US 6573074	B2	20030603		
	EP 1272653	A2	20030108	EP 2001-966770	20010411
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2002004893	A	20021010	NO 2002-4893	20021010
PRAI	US 2000-196361P	P	20000412		
	WO 2001-GB1661	W	20010411		

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from *Actinosynnema pretiosum* containing 86.3 mg/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 mg/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation. At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation. This extract was then dissolved in

toluene,  
loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of

**ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins**.

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from *Actinosynnema pretiosum* containing 86.3 mg/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 mg/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation. At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation. This extract was then dissolved in toluene,  
loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in

toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of

**ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins**.